Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models

Anti-Cancer Drugs

Volumn 7, Issue 8, 1996, Pages 825-832

  Watanabe, Toru ^a,b   Nakayama, Yuji ^a,b   Naito, Mikihiko ^c   Oh hara, Tomoko ^a   Itoh, Yohjiro ^b   Tsuruo, Takashi ^a,c  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b Sandoz Pharmaceuticals Ltd   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

cremophor EL; multidrug resistance; P glycoprotein; PSC 833; tumor bearing mice

Indexed keywords

ANTINEOPLASTIC AGENT; CREMOPHOR; CYCLOSPORIN DERIVATIVE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MITOXANTRONE; PACLITAXEL; VALSPODAR; VINCRISTINE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL LINE; MOUSE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0029769055     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199611000-00002     Document Type: Article

References (25)

1. Tsuruo T. Mechanisms of multidrug resistance and implications for therapy. Jpn J Cancer Res 1988; 79: 285-96.
2. Pastan I, Gottesman MM. Multidrug resistance. Annu Rev Med 1991; 42: 277-86.
3. Tsuruo T, Iida H, Tsukagoshi S, Sukurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-72.
4. Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 1989; 49: 5002-6.
5. Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 1983; 43: 2905-10.
6. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 1983; 43: 2267-72.
7. Slater LM, Sweet P, Stupecky M, Gupta S. Cyclosporine A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 1986; 77: 1405-8.
8. Twentyman PR. Cyclosporines as drug resistance modifiers. Biochem Pharmacol 1992; 43: 109-17.
9. Naito M, Oh-hara T, Yamazaki A, Danki T, Tsuruo T. Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother Pharmacol 1992; 29: 195-200.
10. Woodcock DM, Jefferson S, Linsenmyer ME, et al. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990; 50: 4199-203.
11. Woodcock DM, Linsenmeyer ME, Chojnowski G, et al. Reversal of multidrug resistance by surfactants. Br J Cancer 1992; 66: 62-8.
12. Friche E, Jensen PB, Sehested M, Dement EJF, Nissen NN. The solvents Cremophor EL and Tween80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun 1990; 2: 297-303.
13. Shuurhuis GJ, Broxterman HJ, Pinedo JM, Heijningen HM, Kalken CK, Vermorken JB. The polyoxyethylene castor oil CreEL modifies multidrug resistance. Br J Cancer 1990; 62: 591-4.
14. Boesch D, Gavcriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with PSC 833. Cancer Res 1991; 51: 4226-33.
15. Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. Restoration of Daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 1991; 196: 26-32.
16. Archinal-Mattheis A, Rzepka RW, Watanabe T, et al. Analysis of the interactions of SDZ PSC 833 (13′-keto-Bmt1J-Val2J-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 1995; 7: 603 10.
17. Watanabe T, Tsuge H, Oh-hara T, Naito M, Tsuruo T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporine A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncolog 1995; 34: 235-41.
18. Watanahe T, Naito M, Oh-hara T, Itoh Y, Cohen D, Tsuruo T. Modulation of Multidrug resistance by SDZ PSC 833 in leukemic- and solid-tumor-bearing mice models. Jpn J Cancer Res 1996; 87: 184-93.
19. Tsuruo T, Saito HI, Kawabata H, Oh-hara T, Hamada H, Utakoji T. Characteristics of resistance to Adriamycin in human myelogenous leukemia K562 resistant to Adriamycin and in isolated clones. Jpn J Cancer Res 1988; 79: 285-96.
20. Watanabe T, Inaba M, Sugiyama Y. Saturable process involved in active efflux of vincristine as a mechanism of multidrug resistance in P388 leukemia cells. Pharmac Res 1989; 6: 690-5.
21. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827-33.
22. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 1991; 142: 257 65.
23. Iwahashi T, Okouchi E, Ariyoshi K, et al. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model. Cancer Res 1993; 53: 5475-82.
24. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-99.
25. Webster L, Linsenmeyer M, Millward M, Morion C, Bishop J, Woodcock D. Measurement of Cremophor EL following taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 1993; 85: 1685-90.